KMKatherine G. Meilleur

Katherine G. Meilleur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine G. Meilleur has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Carlos Capella-Peris

    Department of Education and Didactics of Specific Subjects, Universitat Jaume I, Castellón, Spain

    4 shared publications
  • Irene C. Chrismer

    Neuromuscular Symptoms Unit, Tissue Injury Branch, National Institute of Nursing Research, National Institutes of Health, Bethesda, USA

    4 shared publications
  • Mary M. Cosgrove

    Neuromuscular Symptoms Unit, Tissue Injury Branch, National Institute of Nursing Research, National Institutes of Health, Bethesda, USA

    4 shared publications
  • Anna Kuo

    Neuromuscular Symptoms Unit, Tissue Injury Branch, National Institute of Nursing Research, National Institutes of Health, Bethesda, USA

    3 shared publications
  • Jeffrey S. Elliott

    Neuromuscular Symptoms Unit, Tissue Injury Branch, National Institute of Nursing Research, National Institutes of Health, Bethesda, USA

    3 shared publications
  • Magalie Emile-Backer

    Neuromuscular Symptoms Unit, Tissue Injury Branch, National Institute of Nursing Research, National Institutes of Health, Bethesda, USA

    3 shared publications

Latest Publications

  • Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy

    by Laure Le Goff, Katherine G. Meilleur, Gina Norato, Pascal Rippert, Minal Jain, Margaret Fink, A. Reghan Foley, Melissa Waite, Sandra Donkervoort, Carsten G. Bönnemann, et al.


  • Development of a proxy‐reported scale to assess motor function in infants and young children with early‐onset neuromuscular disorders

    by Carlos Capella‐Peris, Magalie Emile‐Backer, Monique O. Shelton, Irene C. Chrismer, Mary M. Cosgrove, Roxanna M. Bendixen, Katherine G. Meilleur

    Aim: To develop a novel proxy‐reported scale of motor function in infants and young children with early‐onset neuromuscular disorders (NMD), entitled the Proxy Motor Outcome Measure (PMOM).Design: A mixed method design was employed, applying both qualitative and quantitative research.Methods: A framework technique using sensitivity analyses guided the development of the most appropriate and relevant subset of items, modelled after 30 neuromuscular disease instruments/scales. The PMOM was designed based on semi‐structured interviews with 16 proxies; a focus group of 11 experts in neuromuscular diseases and scale development, 10 of whom also gave quantitative data using a two‐round Delphi method survey; and cognitive interviews with five proxies. These processes were conducted between January 2014–March 2019.Results: Nine themes and 32 subthemes were derived from the semi‐structured interviews. Five domains and three subdomains of potential items were identified by the focus group. An initial version of the PMOM scale was created with 121 items. Using the two‐round Delphi method, 43 items met agreement on pre‐defined requirements. The second version of the PMOM scale included these 43 and two additional items based on expert feedback. Proxies gave 114 suggestions on cognitive interviews, 99 of which were successfully addressed by the research team. The final version of the PMOM scale included 43 items.Conclusion: We developed a preliminary proxy‐reported instrument, the PMOM, to evaluate motor function in infants and young children with early‐onset NMD.Impact: Proxies hold a wealth of knowledge on their child's motor function during early development, which may complement clinic‐based motor function testing. However, there is no validated measure of motor function that incorporates the observation of proxies of infants and young children with NMD. Future work will be focused on assessing the reliability, validity and responsiveness of the PMOM scale and implementing this tool in clinical studies.


  • Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants’ Experience

    by Carlos Capella-Peris, Mary M. Cosgrove, Irene C. Chrismer, M. Sonia Razaqyar, Jeffrey S. Elliott, Anna Kuo, Magalie Emile-Backer, Katherine G. Meilleur

    Background In rare diseases such as ryanodine receptor 1-related myopathies (RYR1-RM), health-related quality of life (HRQoL) measures are critically important so clinicians and researchers can better understand what symptoms are most important to participants, with the ultimate goal of finding tangible solutions for them. Objectives The main objective of this study was to characterize symptoms in individuals with RYR1-RM to inform future research. A secondary objective of this study was to analyze positive and negative sentiments regarding symptoms and treatment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM. Methods The study used a mixed-methods design applying methodological triangulation. Qualitative data were collected via semi-structured interviews at three visits to characterize symptoms in individuals with RYR1-RM and to analyze treatment effects. Qualitative data were then transformed into quantitative results to measure the frequency with which each symptom was mentioned by participants. Results A total of 12 symptoms were identified as areas of interest to participants with RYR1-RM, highlighting fatigue and weakness as key symptoms. Data transformation categorized more than 1000 citations, reporting a greater number of positive comments for postintervention interviews than for baseline and preintervention visits and that NAC group participants stated more positive comments regarding treatment effect than did the placebo group. Conclusions We present a comprehensive characterization of symptoms in RYR1-RM and how those symptoms influence HRQoL. Furthermore, the introduction of mixed methods may be a valuable way to better understand patient-centered data in rare diseases to support affected individuals in coping with their symptoms.


  • Correction to: Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcysteine therapy

    by Carlos Capella-Peris, Mary M. Cosgrove, Irene C. Chrismer, Magalie Emile-Backer, M. Sonia Razaqyar, Jeffrey S. Elliott, Anna Kuo, Paul G. Wakim, Katherine G. Meilleur

    The article Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcystein

  • Open Access

    Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcysteine therapy

    by Carlos Capella-Peris, Mary M. Cosgrove, Irene C. Chrismer, Magalie Emile-Backer, M. Sonia Razaqyar, Jeffrey S. Elliott, Anna Kuo, Paul G. Wakim, Katherine G. Meilleur

    Purpose To characterize Health-Related Quality of Life (HRQoL) in ambulant individuals with RYR1-RM and to determine if a qualitative PRO tool (subjective self-assessment) complements PROMIS and Neuro-QoL scales to detect changes in HRQoL in ambulant individuals with RYR1-RM post N-acetylcysteine (NAC) treatment. Methods The study used a mixed methods research (MMR) design applying methodological triangulation. Qualitative data were collected via semi-structured interviews using open-ended questions. Quantitative data were gathered through PROMIS and Neuro-QoL instruments. Additionally, qualitative data were transformed into quantitative data for subjective self-assessment and frequency analyses. Results Qualitative results identified five domains and 33 subdomains as areas of interest. The most valuable were the importance of social impacts, the development of several coping strategies, both physical and psychological, and the identification of fatigue and weakness as key symptoms. Data transformation then categorized more than 3100 citations on frequency analyses, globally and by domain, visit, and participant. Regarding quantitative results, there was no clear evidence that any of the three PRO tools captured positive changes as a result of NAC treatment. Conclusion Qualitative results showed a comprehensive characterization of HRQoL in this population based on a symptom/patient-centered approach. These findings will inform future studies. Furthermore, given the similar findings across our multiple methods and endpoints, the introduction of MMR may be a valuable, complementary approach to clinical trials. MMR may be especially useful to incorporate in order to address and follow the FDA’s guidance and prioritization on the inclusion of affected individuals’ perspectives in clinical trials.


  • Open Access

    Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease

    by M. Traoré, G. Landouré, W. Motley, M. Sangaré, K. Meilleur, S. Coulibaly, S. Traoré, B. Niaré, F. Mochel, A. La Pean, et al.

    We studied a Malian family with parental consanguinity and two of eight siblings affected with late-childhood-onset progressive myoclonus epilepsy and cognitive decline, consistent with the diagnosis of Lafora disease. Genetic analysis showed a novel homozygous single-nucleotide variant in the NHLRC1 gene, c.560A>C, producing the missense change H187P. The changed amino acid is highly conserved, and the mutation impairs malin's ability to degrade laforin in vitro. Pathological evaluation showed manifestations of Lafora disease in the entire brain, with particularly severe involvement of the pallidum, thalamus, and cerebellum. Our findings document Lafora disease with severe manifestations in the West African population.